Ketamine is an NMDA receptor antagonist and glutamate modulator with rapid antidepressant
effects in patients with treatment resistant depression (TRD). To gain insights into
the etiopathology of TRD and ketamine’s mechanism of action, we examined gene expression
profiles in patients compared to healthy controls (HC) and in patients before and
after ketamine treatment.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Published by Elsevier Inc.
